Health Care · Electromedical & Electrotherapeutic Apparatus · OTC · CIK 849401 · FYE Mar 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $0.04Day +0.00%Mkt cap $3M1Y −33.8%Off 52W high −66.9%Vol (1Y) 162.1%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,415 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest0.0% of sh out |
| Days to cover1.0d |
| Next report (est.)2026-10-10 |
Short interest is FINRA semi-monthly, settlement 2026-07-15.
| Sales (TTM)$3.3M |
| Earnings (TTM)-$100,374 |
| ROE−18.0% |
| Net margin−3.8% |
| ROIC−33.5% |
| Sales growth 3Y−0.1% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−60.3% |
| 1Y−33.8% |
| 3Y−66.9% |
| 5Y−71.6% |
| 10Y−80.2% |
| Since incept. (ann.)−14.3% |
Total return through 2026-07-30 · series begins 2016-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)162.1% |
| Ann. volatility (3Y)156.6% |
| Sharpe (1Y)0.67 |
| Sharpe (3Y)0.53 |
| Max drawdown (1Y)−75.0% |
| Max drawdown (3Y)−78.6% |
| Beta (3Y vs SPY)0.65 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
No 13F holders on file for ADMT.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-07-10 | — | — | $682,821 | −8.9% |
| 2025-12-31 | 2026-02-13 | $0.00 | — | $803,088 | +7.1% |
| 2025-09-30 | 2025-11-14 | — | — | $887,498 | +5.6% |
| 2025-06-30 | 2025-08-19 | — | — | $973,675 | +13.5% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-10 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
Electronics 55% · Chemical 35% · Engineering 10%
business segments · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
